Until January 2015, Dr. Gunn was Division Head of Novartis Animal Health and a member of the Novartis Executive Committee.
Dr. Gunn joined Novartis in 2003 as Head of Novartis Animal Health, North America and became global head of the Animal Health Business Unit in 2004. In addition to this role, he was Division Head, Novartis Consumer Health, from 2008 to 2011 and served as Head of Corporate Social Responsibility from 2011 to 2014.
Before joining Novartis, Dr. Gunn was president of U.S. based Pharmacia Animal Health. His previous positions included a succession of healthcare executive roles over the course of 18 years as well as nine years as a veterinary surgeon. Dr. Gunn graduated with a bachelor of veterinary medicine and surgery from the Royal (Dick) School of Veterinary Studies in the United Kingdom in 1973. He graduated with a diploma in veterinary state medicine from the same school in 1978. In 2008, he received an honorary doctorate in veterinary medicine and surgery from the University of Edinburgh.
Mr. Brown has served as the principal of Gibbs Hill Pty Ltd., a corporate finance and strategic business advisory firm, since October 2006. He is a Director of Preshafood Pty Ltd, a juice company, and served as its Chairman from December 2010 until July 2014.
Mr. Brown served as Director (Investment Banking) of Investec Wentworth, a financial services business from July 2002 to March 2006, a Director and Melbourne Head of Corporate Finance of Rothschild Australia, a financial services firm, from January 1994 to October 2000, and a Director and Co- head of Mergers & Acquisitions (Australia) at Merrill Lynch, a financial services firm, from July 1992 to January 1994.
Mr. Brown was a Director and Chairman of Senetas Corporation, an Australian-listed public information technology encryption company, from May 2011 to April 2013 and the Founding Chairman of The Conversation Media Group Ltd, a not-for profit academic news organization, from April 2010 to September 2012.
Mr. Brown has a Bachelor of Laws degree from University of Adelaide, Southern Australia.
Dr. Hanna has served as the Vice President of Commercial and Medical Affairs Finance at Genentech Inc., a biotechnology company, since March 2009 and served as its Vice President of Alliance Management and Portfolio Planning from January 2006 to March 2009. He is currently serving as the Chief Executive Officer of ORIC Pharmaceuticals, a privately-held oncology company. He also served as the Chief Financial Officer for the Genentech Foundation from January 2006 to March 2009.
Prior to Genentech, Dr. Hanna served as Vice President of Strategic Planning at Tanox, Inc. from August 2001 to December 2005, and prior to that he served as senior associate and Engagement Manager at McKinsey and Company, a management consulting firm.
Dr. Hanna has a B.A. in Physics from the University of Chicago, attended the Harvard Business School, has a Ph.D. in Physics from Harvard University and has an M.D. from the University of Massachusetts.
Dr. Kilty has previously served as Chief Executive Officer of Argutus Medical Ltd. from March 2008 to December 2010 and currently serves as a scientific advisor to EKF Diagnostics Ltd., which acquired Argutus Medical. Dr. Kilty was the founder of Biotrin Holdings Ltd., a virology diagnostics company, which was sold in 2008 to DiaSorin S.p.A.
Dr. Kilty is also a Founder and past Chairman of the Irish BioIndustry Association from 2003 to 2007. From 2005 to 2009, Dr. Kilty served as co- founder and Chairman of Opsona. From February 1986 to June 1990, Dr. Kilty served as the Group Leader and subsequently Director of Research and Development and Technology Planning Assessment in Switzerland for Baxter Healthcare’s Diagnostics Division.
Since 2011, Dr. Kilty has served as an Adjunct Associate Professor of Medicine and Medicinal Chemistry at University College Dublin. Dr. Kilty has a B.Sc. in Zoology and a Ph.D. in Zoology and Biochemistry from University College Dublin, Ireland. He carried out post-doctoral research in protein chemistry and immunology at the University of Texas at Austin and at University College Dublin.
Dr. McCracken has had a distinguished career in pharmaceutical business development. He has worked as a consultant to and served on the boards of several biopharmaceutical companies focusing on the design and implementation of corporate strategy and business development initiatives.
From February 2011 to September 2013, Dr. McCracken served as the Vice President and Global Head of Business Development and Licensing for Hoffmann-La Roche Inc., a research-focused healthcare company, where he was responsible for global licensing activities, and from October 2009 to February 2011 he served as General Manager, Roche Pharma Japan and Asia Regional Head, Roche Partnering, for Chugai Pharmaceutical Co. Ltd., a subsidiary of F. Hoffmann-La Roche Ltd. based in Tokyo.
From August 2000 to October 2009, Dr. McCracken served as Vice President, Business Development at Genentech. From November 1997 to August 2000, Dr. McCracken served as Vice President of Worldwide Business and Technology Development at Rhone-Poulenc Rorer S.A, a French chemical and pharmaceutical company, and Vice President of Technology Licensing and Alliances at Aventis Pharma, a pharmaceutical company.
Dr. McCracken has a B.S. in Microbiology, an M.S. in Pharmacology and a Doctorate of Veterinary Medicine from The Ohio State University.
Rajiv Patel is a Managing Member at Farallon Capital Management, where he has worked since 1997. Prior to joining, Mr. Patel worked at Donaldson, Lufkin & Jenrette as an investment banker in the project finance department. Mr. Patel received an M.B.A. from Stanford Graduate School of Business and graduated from Cornell University as a Merrill Presidential Scholar with a B.S. in Operations Research and Industrial Engineering.
Dr Heffernan is a Nexvet co-founder, and has served as Chief Executive Officer and a member of the Nexvet board of directors since April 2011. In 2003, Mark co-founded Opsona Therapeutics Ltd., an Irish biotechnology company focused on human mAbs for inflammatory diseases, where he served as Founder and Chief Executive Officer from January 2004 to March 2011 and as a Director from January 2004 to December 2011.
Prior to co-founding Opsona, Mark worked in research and development and business development roles for Antisense Therapeutics Limited and Metabolic Pharmaceuticals Pty Ltd., spin-outs from Circadian Technologies Limited in Australia. Dr. Heffernan has a B.Sc. (Hons.) in Biochemistry and Pharmacology and a Ph.D. in Biochemistry from Monash University (Australia).
Mark’s family includes a dog called Clover and a cat, Mittens.
Mr. Payne has served as founder and Chief Executive Officer of Pet Health Innovations, LLC, an animal health consulting company. From 2005 to January 2012, Mr. Payne was employed with MMI, Inc., which operates the Banfield Pet Hospital, where he served as a Senior Vice President from 2005 to 2006, as Executive Vice President from 2006 to 2007 and as President and Chief Executive Officer from 2007 to January 2012.
While serving as President and Chief Executive Officer of MMI, Mr. Payne also served as a member of the Mars Global Petcare America of Bayer Health Care, Animal Health Division, and as a member of the Human and Animal Health Division’s Global Health Care Team.
Mr. Payne is the current chairman of the American Humane Association, dedicated to the protection of animals and children from cruelty, abuse and neglect.
Mr. Payne has a B.A. in Secondary Education from St. Bernard College and an M.B.A from Rockhurst University.
Unit 5, Sragh Technology Park
Rahan Road, Tullamore
Co. Offaly, R35 FR98
P: + 353 5793 24522
Level 8, 31 Queen Street
P: +61 (3) 9610 4400
275 Post Street
San Francisco, CA 94108